Cargando…

Glucagon-Like Peptide-1 and Diabetes

Detalles Bibliográficos
Autor principal:	Monami, Matteo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2011
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3235767/ https://www.ncbi.nlm.nih.gov/pubmed/22203831 http://dx.doi.org/10.1155/2011/901954

Ejemplares similares

Glucagon-Like Peptide-1 and Diabetes 2012
por: Monami, Matteo, et al.
Publicado: (2012)

Glucagon-Like Peptide-1, Diabetes, and Cognitive Decline: Possible Pathophysiological Links and Therapeutic Opportunities
por: Mossello, Enrico, et al.
Publicado: (2011)

Effects of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight: A Meta-Analysis
por: Monami, Matteo, et al.
Publicado: (2012)

Is there a role for glucagon-like peptide-1 receptor agonists in the management of diabetic nephropathy?
por: Veneti, Stavroula, et al.
Publicado: (2020)

Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Events: A Meta-Analysis of Randomized Clinical Trials
por: Monami, Matteo, et al.
Publicado: (2011)

Newer Vistas in Glucagon-Like Peptide-1 Analog Therapy - Marvels of Peptide Engineering
por: Jacob, Jubbin Jagan, et al.
Publicado: (2021)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

Dipeptidyl peptidase IV inhibitors in diabetes: more than inhibition of glucagon-like peptide-1 metabolism?
por: Michel, Martin C., et al.
Publicado: (2008)

Glucagon-like peptide 1 and Glucagon-like peptide 2 in relation to osteoporosis in non-diabetic postmenopausal women
por: Montes Castillo, María Cristina, et al.
Publicado: (2019)

Exercise and glucagon-like peptide-1: Does exercise potentiate the effect of treatment?
por: Hamasaki, Hidetaka
Publicado: (2018)

New concept of the glucagon‐like peptide‐1 signaling pathway on pancreatic insulin secretion
por: Kaku, Kohei
Publicado: (2019)

Should glucagon‐like peptide‐1 receptor agonist treatment be withheld in preoperative management?
por: Bloomgarden, Zachary
Publicado: (2023)

Computational Peptide Design Cotargeting Glucagon and Glucagon-like Peptide-1 Receptors
por: Vishnoi, Shubham, et al.
Publicado: (2023)

Stability of glucagon-like peptide 1 and glucagon in human plasma
por: Wewer Albrechtsen, Nicolai J, et al.
Publicado: (2015)

The Possible Protective Role of Glucagon-Like Peptide 1 on Endothelium During the Meal and Evidence for an “Endothelial Resistance” to Glucagon-Like Peptide 1 in Diabetes
por: Ceriello, Antonio, et al.
Publicado: (2011)

Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration
por: Ammann, Markus, et al.
Publicado: (2023)

Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 Receptor
por: Underwood, Christina Rye, et al.
Publicado: (2010)

Exenatide at mealtimes in type 1 diabetes—no MAG1C with exenatide, or with other glucagon-like peptide-1 receptor agonists
por: Doggrell, Sheila A.
Publicado: (2020)

Glycemic monitoring with once-weekly Glucagon-like peptide 1 receptor agonist (GLP1RA) use
por: Kalra, Sanjay, et al.
Publicado: (2015)

Glucagon-like peptide 1 (GLP-1)
por: Müller, T.D., et al.
Publicado: (2019)

Regulation of intestinal lipid and lipoprotein metabolism by the proglucagon-derived peptides glucagon like peptide 1 and glucagon like peptide 2
por: Mulvihill, Erin E.
Publicado: (2018)

Polymer-Based Delivery of Glucagon-Like Peptide-1 for the Treatment of Diabetes
por: Kim, Pyung-Hwan, et al.
Publicado: (2012)

Glucagon−like Peptide−1 and−2 Levels in Children with Diabetic Ketoacidosis
por: Akıncı, Ayşehan, et al.
Publicado: (2009)

Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
por: Hinnen, Deborah
Publicado: (2017)

Glucagon-Like Peptide 1: A Predictor of Type 2 Diabetes?
por: Larsen, Matthias Ploug, et al.
Publicado: (2017)

Glucagon‐like peptide‐1 therapy for youth with type 2 diabetes
por: Cho, Young Min
Publicado: (2022)

Unlocking the Therapeutic Potential of Glucagon-Like Peptide-1 Analogue and Fibroblast Growth Factor 21 Combination for the Pathogenesis of Atherosclerosis in Type 2 Diabetes
por: Son, Jang Won
Publicado: (2021)

Glucagon-Like Peptide-1 Gene Therapy
por: Rowzee, Anne M., et al.
Publicado: (2011)

Glucagon-like peptide-1 analogues: An overview
por: Gupta, Vishal
Publicado: (2013)

Glucagon-like peptide 1 improved glycemic control in type 1 diabetes
por: Behme, Margaret T, et al.
Publicado: (2003)

Disparities in the Use of SGLT2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Adults With CKD in the United States
por: Nicholas, Susanne B., et al.
Publicado: (2022)

Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates kidney injury in murine models of obesity and diabetes mellitus
por: Patel, Vishal J, et al.
Publicado: (2018)

Salivary Hormones Leptin, Ghrelin, Glucagon, and Glucagon-Like Peptide 1 and Their Relation to Sweet Taste Perception in Diabetic Patients
por: Al-Ghurayr, Nada K., et al.
Publicado: (2023)

Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
por: Pocai, Alessandro, et al.
Publicado: (2009)

Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes
por: Raven, Lisa M, et al.
Publicado: (2022)

Direct cardiovascular effects of glucagon like peptide-1
por: Sheikh, Asfandyar
Publicado: (2013)

Is ghrelin a glucagon‐like peptide‐1 secretagogue?
por: Ueno, Hiroaki, et al.
Publicado: (2015)

Equine glucagon-like peptide-1 receptor physiology
por: Kheder, Murad H., et al.
Publicado: (2018)

Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1
por: Paternoster, Silvano, et al.
Publicado: (2018)

Levels of glucagon-like peptide 1 in hyperemesis gravidarum
por: Aktulay, Ayla, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_chs6hbjq4nb68r7lr864sjd4ls